ClinicalTrials.gg
Active, not recruitingNCT04537871Updated Aug 14, 2026

Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study

An observational study in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by City of Hope Medical Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center — 10 open to participants now, 28 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · City of Hope Medical Center.

Started
2020
with 3 others
Observational
5 of 55
none open now
Primary completion
2027-05
later than 10 of 27 live
Registered
39th of 55
by date

Among the 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center, this one is one of 4 that started in 2020, is one of 5 observational ones, reaches primary completion later than 10 of the 27 other live ones, and was the 39th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

10 of the 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by City of Hope Medical Center, or all of them as a file.
02

Study summary

This study evaluates how well the heart, lungs, and muscles are working individually, and how these systems are working together in transplant survivors. Information collected in this study may help doctors to understand why hematopoietic stem cell transplant survivors are at higher risk for developing cardiovascular disease.

Read the detailed description

PRIMARY OBJECTIVES:

I. Evaluate cardiovascular reserve capacity, as measured by peak oxygen consumption (VO2peak), in hematopoietic cell transplantation (HCT) survivors.

II. Define the determinants of VO2peak impairment in HCT survivors.

OUTLINE:

Patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance analysis to measure total lean body mass and percent body fat), physical function tests, and collection of blood samples within 45 days from the start of conditioning therapy, and at 6 months, 1 year, and 2 years post-transplant.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Hodgkin Lymphoma
  • Myelodysplastic Syndrome
  • Non-Hodgkin Lymphoma
  • Plasma Cell Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute leukemia (myeloid, lymphoid), lymphoma (non-Hodgkin, Hodgkin), multiple myeloma or myelodysplastic syndromes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age at HCT >= 18 years
  • Diagnosis of acute leukemia (myeloid, lymphoid), lymphoma (non-Hodgkin, Hodgkin), multiple myeloma or myelodysplastic syndromes
  • Planning to undergo first or allogeneic transplant
  • Able to fluently read and write in English
  • Able to understand and sign the study specific form (ICF)
  • Physically able and willing to complete all study procedures

Exclusion criteria

Exclusion Criteria:

  • Unstable bone lesions per electronic medical record review and/or notification from patient's primary physician
  • Unstable angina or history of acute myocardial Infarction (\< 5 days of any planned study procedures)
  • Recurrent syncope
  • Acute myocarditis or pericarditis
  • Symptomatic severe aortic stenosis
  • Uncontrolled arrhythmia causing symptoms
  • Pulmonary embolus \< 3 month of study procedures
  • Thrombosis of lower extremities
  • Moderate or severe persistent asthma (National Asthma Education \& Prevention)
  • Room air desaturation at rest =\< 85%
  • Non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis)
  • Anemia ( [Hgb] \< 8 g/dL)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Observational (physical assessment)

    Patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance analysis to measure total lean body mass and percent body fat), physical function tests, and collection of blood samples within 45 days from the start of conditioning therapy, and at 6 months, 1 year, and 2 years post-transplant.

    Procedure: Bioelectric Impedance Analysis · Procedure: Biospecimen Collection · Procedure: Cardiopulmonary Exercise Testing · Procedure: Echocardiography · Procedure: Physical Performance Testing · Procedure: Pulmonary Function Test · Other: Questionnaire Administration · Procedure: Ultrasound

Interventions

  • ProcedureBioelectric Impedance Analysis

    Undergo bioelectric impedance analysis

    Also known as: BIA, Bioelectric Impedance, Bioelectric Impedance Test, Bioelectrical Impedance Analysis, Bioimpedance Analysis

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

  • ProcedureCardiopulmonary Exercise Testing

    Undergo cardiopulmonary exercise test

    Also known as: CPET, CPX

  • ProcedureEchocardiography

    Undergo echocardiogram

  • ProcedurePhysical Performance Testing

    Undergo physical function tests

    Also known as: Physical Fitness Testing, Physical Function Testing

  • ProcedurePulmonary Function Test

    Undergo pulmonary function test

    Also known as: lung function test, PFT, Pulmonary Function Testing, Pulmonary Function Tests

  • OtherQuestionnaire Administration

    Ancillary studies

  • ProcedureUltrasound

    Undergo musculoskeletal ultrasound

06

What researchers measure

Primary outcomes

  1. Cardiovascular reserve capacity, as measured by VO2peak, in HCT survivors

    We will measure initial VO2peak in patients prior to HCT and its post-HCT trajectory over time; compare VO2peak in HCT survivors at baseline (pre-HCT), 6m, 1Y, and 2Y post-HCT to established age- and sex-normative data; and define the association between VO2peak and self-reported health-related quality of life (HRQOL) at baseline/over time.

    Time frame: Up to 24 months post-hematopoietic cell transplantation (HCT)

  2. Determinants of VO2peak impairment in HCT survivors

    We will use Generalized Estimating Equation(GEE) and generalized linear models to examine the correlation between VO2peak and measures of: 1. cardiac (left ventricular function/ contractility \[systolic, diastolic, cardiac output, strain\], ventricular-arterial (VA) coupling, arterial elastance); 2. pulmonary (obstructive, restrictive lung disease, diffusion capacity); 3. musculoskeletal (body composition \[% lean muscle mass\], muscle quality, two minute step in place test, 30 second sit to stand test, timed up and go); and 4. hematologic function, adjusting for potential confounding variables (e.g. age, sex) and time since HCT.

    Time frame: Up to 24 months post-hematopoietic cell transplantation (HCT)

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for May 2027, 78 months after the start.

Of 145 non-industry observational studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 143. This study's planned 78 months is above that.

Counting every sponsor, half of 163 studies reached it within 49 months; a quarter within 22 and three quarters within 142.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2020
First posted
Sep 3, 2020
StartActual
Nov 18, 2020
Primary completionEst.
May 25, 2027
CompletionEst.
May 25, 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04537871
Responsible party
Sponsor
First posted
Sep 3, 2020
Start date
Nov 18, 2020
Primary completion
May 25, 2027 (estimated)
Completion
May 25, 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

Saro H Armenian
principal investigator · City of Hope Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion